Skip to main content
. Author manuscript; available in PMC: 2022 May 28.
Published in final edited form as: Cancer Lett. 2021 Mar 6;506:95–106. doi: 10.1016/j.canlet.2021.03.002

Figure 4. IRF-1 recruits immune cells to enhance apoptosis in murine HCC tumor.

Figure 4.

A, B) The statistical summary of cells count in CD3+, CD4+, CD8+ T cells, and NK and NKT cells in the medium of Hepa1–6 cells overexpressing IRF-1 (IRF-1) vs. negative control (NC) in the lower chamber of transwell plate. C) Tumor images (upper) and growth curves (lower, mean ± SEM) of murine HCC tumor overexpressing IRF-1 (lower) vs. negative control (upper). D) Representative images of FACS assay for apoptotic (Annexin V+PI+) cell rate in single cell suspensions prepared from same volume of tumors expressing IRF-1 vs. NC. E) The statistical summary of apoptotic tumor cells rate in tumors expressing IRF-1 vs. NC. F) qRT-PCR analysis for CD8a, GZMB and IFN-γ mRNA expression in tumors expressing IRF-1 vs. NC. G, H) The statistical summary of NK cells, NKT cells and CD19+ B cells rate, as well as CD3+, CD4+ and CD8+ T cells rate in tumors expressing IRF-1 vs. NC. Representative images of FACS assay for NK cells or CD19+ B cells rate (I), NKT cells rate (J), CD4+ or CD8+ T cells rate (K) in single cell suspensions prepared from same volume of tumors expressing IRF-1 vs. NC. Each data point (A, B) represents an independent experiment (n=3). Each data point (E, F, G & H) represents one mouse (n=5). Data represent mean ± SD, *p<0.05, **p<0.01. (NS, no significant).